NovoLog FlexPen Sales Data
| Rank 34 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows NovoLog FlexPen U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 34 ( 1) |
$364,870 | 7.84% | 3,030 | 1.13% |
| Q3 2013 | 33 ( 6) |
$338,348 | 4.54% | 2,996 | -2.82% |
| Q2 2013 | 39 (4) |
$323,641 | 2.10% | 3,083 | 3.49% |
| Q1 2013 | 43 (1) |
$316,981 | 7.97% | 2,979 | -1.52% |
| Q4 2012 | 42 (9) |
$293,569 | 8.43% | 3,025 | 10.32% |
| Q3 2012 | 51 (12) |
$270,735 | 11.89% | 2,742 | 3.28% |
| Q2 2012 | 63 (11) |
$241,972 | 6.49% | 2,655 | 6.67% |
| Q1 2012 | 74 (2) |
$227,228 | 8.96% | 2,489 | 13.81% |
| Q4 2011 | 76 (4) |
$208,552 | 10.19% | 2,187 | 6.73% |
| Q3 2011 | 80 (6) |
$189,267 | 4.15% | 2,049 | 4.92% |
| Q2 2011 | 86 (7) |
$181,733 | 3.71% | 1,953 | 29.60% |
| Q1 2011 | 93 | $175,235 | n/a | 1,507 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
